Clinical trial NCT06564818: "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Official title: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Major Depressive Disorder
Keywords: Major Depressive Disorder
MDD
Psilocybin
Psychedelic
Psilocin
CYB003
CYB003-001
Depression
Lead sponsor: Cybin IRL Limited
Sponsor class: INDUSTRY
Collaborators: name: Worldwide Clinical Trials
First posted: 2024-08-21
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.


Eligibility criteria: Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

* Aged 18 to 85 years inclusive, at Screening
* Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \[if single episode, duration of ≥4 weeks and ≤24 months\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
* Depression is of moderate to severe degree at Screening, independently confirmed by additional clinical assessments
* Participant has been on a stable dose of a single antidepressant medication at an adequate dose (label specified) for an adequate duration in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator and clinical interviews.
* Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤ 40 kg/m2), inclusive, at Screening.
* Participant is able to refrain from nicotine use during the dosing session (up to 8 hours)
* Registered with a healthcare professional who can confirm the diagnosis and previous treatments received by the participant.
* Participants capable of producing sperm must use a condom during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential. In addition, their partner of childbearing potential must use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) from first dosing until 12 weeks following final dosing.
* Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day -1 prior to dosing.
* Female participants who were capable of producing eggs (ova) must be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle-stimulating hormone level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception.
* Participant has provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria:

Participants with any of the following characteristics/conditions will be excluded from trial participation:

* Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, attention deficit hyperactivity disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
* Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first degree relatives).
* Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
* Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose for an adequate duration as judged by the Investigator and clinical interview.
* Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
* Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, or an antipsychotic or mood stabilizer for MDD.
* Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 4 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
* Clinically relevant history of abnormal physical health interfering with the trial as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder).
* Participants with renal insufficiency.
* Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication with no change in dosage for at least 12 weeks prior to Screening.
* Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate or blood pressure
* History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the trial medication.
* Participant has a presence or relevant history of organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).
* Known sensitivity to psilocin and/or any excipients present in the formulation.
* Participant is taking or has taken OTC doses of 5 hydroxytryptophan or St John's Wort within 45 days prior to trial medication administration.
* Strenuous exercise within 48 hours prior to each clinic visit.
* The participant has participated in a clinical trial and has received a medication or a new chemical entity within 12 weeks prior to dosing of current trial medication.
* Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
* Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
* History of serotonin syndrome.
* Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Primary outcomes:
measure: Montgomery-Åsberg Depression Rating Scale (MADRS)
timeFrame: Screening Day-45, Baseline Day-1, Day 2, Day 10, Day 21, Day 23, Day 31, and Day 42 (End of Treatment)
Secondary outcomes:
measure: The Beck Depression Inventory-Second Edition (BDI-II)
timeFrame: Baseline Day-1, Day 21, and Day 42 (End of Treatment)
measure: The Clinical Global Impression Scale (CGI-S)
timeFrame: Screening Day-45, Baseline Day-1, and Day 42 (End of Treatment)
measure: The Generalized Anxiety Disorder 7-item scale (GAD-7)
timeFrame: Baseline Day-1, Day 21, and Day 42 (End of Treatment)
measure: The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
timeFrame: Baseline Day-1, Day 21, and Day 42 (End of Treatment)
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Noble Clinical Research
state: Arizona
city: Bellflower
country: United States
facility: CenExel CIT (Clinical Innovations, Inc)
state: California
city: La Jolla
country: United States
facility: Kadima Neuropsychiatry Institute
state: California
city: San Francisco
country: United States
facility: Open Mind Collective/UCSF Medical Center Mount Zion
state: California
city: San Juan Capistrano
country: United States
facility: Inland Psychiatric Medical Group Inc
state: California
city: Santa Monica
country: United States
facility: Pacific Neuroscience Institute
state: California
city: Denver
country: United States
facility: Mountain View Clinical Research
state: Colorado
city: Hollywood
country: United States
facility: Research Centers of America
state: Florida
city: Maitland
country: United States
facility: K2 Medical Research-Maitland
state: Florida
city: Miami
country: United States
facility: Floridian Neuroscience Institute
state: Florida
city: North Miami
country: United States
facility: Innovative Clinical Research, INC
state: Florida
city: Orlando
country: United States
facility: Clinical Neuroscience Solutions, Inc
state: Florida
city: Tampa
country: United States
facility: K2 Medical Research-Tampa
state: Florida
city: Atlanta
country: United States
facility: Atlanta Center for Medical Research, CenExel
state: Georgia
city: Decatur
country: United States
facility: CenExel iResearch Atlanta
state: Georgia
city: Savannah
country: United States
facility: CenExel iResearch Savannah
state: Georgia
city: Chicago
country: United States
facility: Uptown Research Institute
state: Illinois
city: Rockville
country: United States
facility: Sunstone Medical, PC
state: Maryland
city: Boston
country: United States
facility: Adams Clinical
state: Massachusetts
city: New York
country: United States
facility: Nautilus Psychiatric Services, PLLC
state: New York
city: North Canton
country: United States
facility: Neurobehavioral Clinical Research
state: Ohio
city: Memphis
country: United States
facility: Clinical Neuroscience Solutions, CNS Healthcare
state: Tennessee
city: DeSoto
country: United States
facility: InSite Clinical Research, LLC
state: Texas
city: Plano
country: United States
facility: AIM Trials
state: Texas
city: Murray
country: United States
facility: Cedar Clinical Research
state: Utah
Study officials:
affiliation: Cybin IRL Limited
name: Felix Mazer
role: STUDY_DIRECTOR
References: